Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells

Leukemia Research

Volumn 38, Issue 2, 2014, Pages 251-257

  Machado Neto, João Agostinho ^a   De Melo Campos, Paula ^a   Favaro, Patricia ^a,b   Lazarini, Mariana ^a   Lorand Metze, Irene ^a   Costa, Fernando Ferreira ^a   Olalla Saad, Sara Teresinha ^a   Traina, Fabiola ^a,c  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acute lymphoid leukemia; Acute myeloid leukemia; Myelodysplastic syndromes; OP18; Stathmin 1

Indexed keywords

STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG; STMN1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CELL LEVEL; CELL PROLIFERATION; CELL STRAIN NAMALWA; CLONOGENESIS; FEMALE; GENE SILENCING; HEMATOPOIETIC CELL; HIGH RISK POPULATION; HUMAN; LEUKEMIA CELL; LEUKEMIA CELL LINE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELODYSPLASTIC SYNDROME CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; GENETICS; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RISK; TUMOR CELL CULTURE; TUMOR INVASION; U937 CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL PROLIFERATION; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM INVASIVENESS; PHENOTYPE; RISK; STATHMIN; TUMOR CELLS, CULTURED; U937 CELLS; YOUNG ADULT;

EID: 84892517533     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.11.013     Document Type: Article

References (23)

1. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:692-701.
2. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108:2358-2365.
3. Rubin C.I., Atweh G.F. The role of stathmin in the regulation of the cell cycle. J Cell Biochem 2004, 93:242-250.
4. Belletti B., Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 2011, 15:1249-1266.
5. Hanash S.M., Strahler J.R., Kuick R., Chu E.H., Nichols D. Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 1988, 263:12813-12815.
6. Melhem R.F., Zhu X.X., Hailat N., Strahler J.R., Hanash S.M. Characterization of the gene for a proliferation-related phosphoprotein (oncoprotein 18) expressed in high amounts in acute leukemia. J Biol Chem 1991, 266:17747-17753.
7. Bigarella C.L., Ferro K.P., Barcellos K.S., Martins-de-Souza D., Traina F., Novello J.C., et al. Post-translational modification of the RhoGTPase activating protein 21, ARHGAP21, by SUMO2/3. FEBS Lett 2012, 586:3522-3528.
8. Williams K., Ghosh R., Giridhar P.V., Gu G., Case T., Belcher S.M., et al. Inhibition of stathmin1 accelerates the metastatic process. Cancer Res 2012, 72:5407-5417.
9. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
10. Machado-Neto J.A., Favaro P., Lazarini M., Costa F.F., Olalla Saad S.T., Traina F. Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. Biochim Biophys Acta 2011, 1813:1404-1411.
11. Barcellos K.S., Bigarella C.L., Wagner M.V., Vieira K.P., Lazarini M., Langford P.R., et al. ARHGAP21 protein, a new partner of alpha-tubulin involved in cell-cell adhesion formation and essential for epithelial-mesenchymal transition. J Biol Chem 2013, 288:2179-2189.
12. Roos G., Brattsand G., Landberg G., Marklund U., Gullberg M. Expression of oncoprotein 18 in human leukemias and lymphomas. Leukemia 1993, 7:1538-1546.
13. Melhem R., Hailat N., Kuick R., Hanash S.M. Quantitative analysis of OP18 phosphorylation in childhood acute leukemia. Leukemia 1997, 11:1690-1695.
14. Marafioti T., Copie-Bergman C., Calaminici M., Paterson J.C., Shende V.H., Liu H., et al. Another look at follicular lymphoma: immunophenotypic and molecular analyses identify distinct follicular lymphoma subgroups. Histopathology 2013, 62:860-875.
15. Karst A.M., Levanon K., Duraisamy S., Liu J.F., Hirsch M.S., Hecht J.L., et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011, 123:5-12.
16. Baquero M.T., Hanna J.A., Neumeister V., Cheng H., Molinaro A.M., Harris L.N., et al. Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer. Cancer 2012, 118:4660-4669.
17. Hsieh S.Y., Huang S.F., Yu M.C., Yeh T.S., Chen T.C., Lin Y.J., et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010, 49:476-487.
18. Chen J., Abi-Daoud M., Wang A., Yang X., Zhang X., Feilotter H.E., et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene 2013, 32:1330-1337.
19. Jeon T.Y., Han M.E., Lee Y.W., Lee Y.S., Kim G.H., Song G.A., et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010, 102:710-718.
20. Kang W., Tong J.H., Chan A.W., Lung R.W., Chau S.L., Wong Q.W., et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS ONE 2012, 7:e33919.
21. Rubin C.I., French D.L., Atweh G.F. Stathmin expression and megakaryocyte differentiation: a potential role in polyploidy. Exp Hematol 2003, 31:389-397.
22. Jeha S., Luo X.N., Beran M., Kantarjian H., Atweh G.F. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996, 56:1445-1450.
23. Jiang H., Schiffer E., Song Z., Wang J., Zurbig P., Thedieck K., et al. Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A 2008, 105:11299-11304.